Hydroxyurea

Back to search
Scientific Name: Hydroxyurea
Brand Name: Droxia, Hydrea, Siklos
Company Owner: Bristol myers squibb co, Barr laboratories inc, Duramed pharmaceuticals inc sub barr laboratories inc, Par pharmaceutical inc, Roxane laboratories inc, Hospira inc
Mechanism Of Action Hydroxyurea is converted to a free radical nitroxide (NO) in vivo, and transported by diffusion into cells where it quenches the tyrosyl free radical at the active site of the M2 protein subunit of ribonucleotide reductase, inactivating the enzyme. The entire replicase complex, including ribonucleotide reductase, is inactivated and DNA synthesis is selectively inhibited, producing cell death in S phase and synchronization of the fraction of cells that survive. Repair of DNA damaged by chemicals or irradiation is also inhibited by hydroxyurea, offering potential synergy between hydroxyurea and radiation or alkylating agents. Hydroxyurea also increases the level of fetal hemoglobin, leading to a reduction in the incidence of vasoocclusive crises in sickle cell anemia. Levels of fetal hemoglobin increase in response to activation of soluble guanylyl cyclase (sGC) by hydroxyurea-derived NO.
Description of the Drug: Hydroxyurea is an antimetabolite used to treat sickle cell anemia crisis.
Protein Data Bank:
Source: DrugBank Online – DrugBank.com. Retrieved 2023-01-23 from https://go.drugbank.com/drugs/DB01005